Indaptus Therapeutics (Indaptus Therapeutics) Interest Expense : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Indaptus Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Indaptus Therapeutics's interest expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Indaptus Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -4.18 Mil. Indaptus Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ 0.00 Mil. GuruFocus does not calculate Indaptus Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Indaptus Therapeutics Interest Expense Historical Data

The historical data trend for Indaptus Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indaptus Therapeutics Interest Expense Chart

Indaptus Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

Indaptus Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial										-	-	-	-	-

Indaptus Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Indaptus Therapeutics (NAS:INDP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Indaptus Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-4.18 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.07 Mil.

Indaptus Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate Indaptus Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Indaptus Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Indaptus Therapeutics (Indaptus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Columbus Circle, 15th Floor, New York, NY, USA, 10019

Website

https://www.indaptusrx.com

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.

Executives

Glen R. Anderson	10 percent owner	3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman	officer: Chief Medical Officer	C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell	director	4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev	officer: Chief Medical Officer	13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler	director, officer: Chief Executive Officer	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott	officer: Chief Business Officer	1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman	director, 10 percent owner, officer: Chief Scientific Officer	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert	director	13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee	director, 10 percent owner	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes	director	231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah	director	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi	officer: Chief Financial Officer	3 ELUL STREET, APT. 6, MODIIN L3 7176397